Granulocyte-macrophage-colony-stimulating factor-dependent peritoneal macrophage responses determine survival in experimentally induced peritonitis and sepsis in mice

Shock

Volumn 30, Issue 4, 2008, Pages 434-442

  Spight, Donn ^a   Trapnell, Bruce ^b   Zhao, Bin ^b   Berclaz, Pierre ^b   Shanley, Thomas P ^c  

^a UNIVERSITY OF CINCINNATI   (United States)

^b CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cecal ligation and puncture; Granulocyte macrophage colony stimulating factor; Macrophage; Sepsis

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY LIGATION; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; IN VITRO STUDY; INNATE IMMUNITY; MICROFLORA; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PERITONITIS; SEPSIS; SURVIVAL;

ANIMALS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNE SYSTEM; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PERITONITIS; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54049119495     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181673543     Document Type: Article

References (50)

1. Angus DC, Wax RS: Epidemiology of sepsis: an update. Crit Care Med 29:S109-S116, 2001.
2. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Heiterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001.
3. Read RC, Wyllie DH: Toll receptors and sepsis. Curr Opin Crit Care 7:371-375, 2001.
4. Brightbill HD, Modlin RL: Toll-like receptors: molecular mechanisms of the mammalian immune response. Immunology 101:1-10, 2000.
5. Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 406:782-787, 2000.
6. Beutler B, Du X, Poltorak A: Identification of Toll-like receptor 4 (Tlr4) as the sole conduit for LPS signal transduction: genetic and evolutionary studies. J Endotoxin Res 7:277-280, 2001.
7. Bone RC: Sepsis syndrome. New insights into its pathogenesis and treatment. Infect Dis Clin North Am 5:793-805, 1991.
8. Parent C, Eichacker PQ: Neutrophil and endothelial cell interactions in sepsis. The role of adhesion molecules. Infect Dis Clin North Am 13:427-447, 1999.
9. Bone RC: Why sepsis trials fail. JAMA 276:565-566, 1996.
10. Dinarello CA: Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. J Biol Regul Homeost Agents 11:91-103, 1997.
11. Dinarello CA: Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 112:321S-329S, 1997.
12. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24:1125-1128, 1996.
13. Woiciechowsky C, Asadullah K, Nestler D, Schoning B, Glockner F, Docke WD, Volk HD: Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: effect of tumor extirpation. J Neuroimmunol 84:164-171, 1998.
14. Asadullah K, Woiciechowsky C, Docke WD, Egerer K, Kox WJ, Vogel S, Sterry W, Volk HD: Very low monocytic HLA-DR expression indicates high risk of infection - immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med 2:184-190, 1995.
15. Hynninen M, Pettila V, Takkunen O, Orko R, Jansson SE, Kuusela P, Renkonen R, Valtonen M: Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis. Shock 20:1-4, 2003.
16. Volk HD, Thieme M, Heym S, Docke WD, Ruppe U, Tausch W, Manger D, Zuckermann S, Golosubow A, Nieter B, et al.: Alterations in function and phenotype of monocytes from patients with septic disease - predictive value and new therapeutic strategies. Behring Inst Mitt 208-215, 1991.
17. Flohe S, Lendemans S, Selbach C, Waydhas C, Ackermann M, Schade FU, Kreuzfelder E: Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma. Crit Care Med 31:2462-2469, 2003.
18. Nierhaus A, Montag B, Timmler N, Frings DP, Gutensohn K, Jung R, Schneider CG, Pothmann W, Brassel AK, Schulte Am Esch J: Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 29:646-651, 2003.
19. Hamilton JA, Anderson GP: GM-CSF biology. Growth Factors 22:225-231, 2004.
20. Berclaz PY, Carey B, Fillipi MD, Wernke-Dollries K, Geraci N, Cush S, Richardson T, Kitzmiller J, O'Connor M, Hermoyian C, et al.: GM-CSF regulates a PU.1-dependent transcriptional program determining the pulmonary response to LPS. Am J Respir Cell Mol Biol 36:114-121, 2007.
21. Uchida K, Beck DC, Yamamoto T, Berclaz PY, Abe S, Staudt MK, Carey BC, Filippi MD, Wert SE, Denson LA, et al.: GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 356:567-579, 2007.
22. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whilsett JA, Trapnell BC: GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 15:557-567, 2001.
23. Trapnell BC, Whitsett JA: GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Annu Rev Physiol 64:775-802, 2002.
24. Dranoff G, Mulligan RC: Activities of granulocyte-macrophage colony-stimulating factor revealed by gene transfer and gene knockout studies. Stem Cells 12:173-182, 1994; discussion 182-184.
25. Huffman JA, Hull WM, Dranoff G, Mulligan RC, Whitsett JA: Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J Clin Invest 97:649-655, 1996.
26. Zingarelli B, Hasko G, Salzman AL, Szabo C: Effects of a novel guanylyl cyclase inhibitor on the vascular actions of nitric oxide and peroxynitrite in immunostimulated smooth muscle cells and in endotoxic shock. Crit Care Med 27:1701-1707, 1999.
27. Berclaz PY, Shibata Y, Whitsett JA, Trapnell BC: GM-CSF, via PU.1. regulates alveolar macrophage Fcgamma R-mediated phagocytosis and the IL-18/IFN-gamnta-mediated molecular connection between innate and adaptive immunity in the lung. Blood 100:4193-4200, 2002.
28. Cerami A, Beutler B: The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today 9:28-31, 1988.
29. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP: High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med 91:23-29, 1991.
30. Iwamura H, Sato M, Wakitani K: Comparative study of glucocorticoids, cyclosporine A, and JTE-607 [(-)-Ethyl-N[3,5-dichloro-2-hydroxy-4-[2-(4- methylpiperazin-1-yl)ethoxy]be nzoyl]-L-phenylalaninate dihydrochloride] in a mouse septic shock model. J Pharmacol Exp Titer 311:1256-1263, 2004.
31. Gao H, Neff TA, Guo RF, Speyer CL, Sarma JV, Tomlins S, Man Y, Riedemann NC, Hoesel LM, Younkin E, et al.: Evidence for a functional role of the second C5a receptor C5L2. FASEB J 19:1003-1005, 2005.
32. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA: Six at six: interlcukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463-467, 2002.
33. Berclaz PY, Zsengeller Z, Shibata Y, Otake K, Strasbaugh S, Whitsett JA, Trapnell BC: Endocytic internalization of adenovirus, nonspecific phagocytosis, and cytoskeletal organization are coordinately regulated in alveolar macrophages by GM-CSF and PU.1. J Immunol 169:6332-6342, 2002.
34. Remick DG, Ncwcomb DE, Bolgos GL, Call DR: Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13:110-116, 2000.
35. Ebong SJ, Call DR, Bolgos G, Newcomb DE, Granger JI,O'Reilly M, Remick DG: Immunopathologic responses to non-lethal sepsis. Shock 12:118-126, 1999.
36. Bonfield TL, Raychaudhuri B, Malur A, Abraham S, Trapnell BC, Kavuru MS, Thomassen MJ: PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor. Am J Physiol Lung Cell Mol Physiol 285:L1132- L1136, 2003.
37. del Fresno C, Soler-Rangel L, Soares-Schanoski A, Gomez-Pina V, Gonzalez-Leon MC, Gomez-Garcia L, Mendoza-Barbera E, Rodriguez-Rojas A, Garcia F, Fuentes-Prior P, et al.: Inflammatory responses associated with acute coronary syndrome up-regulate IRAK-M and induce endotoxin tolerance in circulating monocytes. J' Endotoxin Res 13:39-52, 2007.
38. Fan H, Cook JA: Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 10:71-84, 2004.
39. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr. Medzhitov R, Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110:191-202, 2002.
40. Watson RS, Linde-Zwirble WT, Carcillo JA, Angus DC: Severe sepsis in children: a U.S. Epidemiologic Survey. Crit Care Med 28:A46, 2001.
41. Suri M, Harrison L, Van de Ven C, Cairo MS: Immunotherapy in the prophylaxis and treatment of neonatal sepsis. Curr Opin Pediatr 15:155-160, 2003.
42. Banerjea MC, Speer CP: The current role of colony-stimulating factors in prevention and treatment of neonatal sepsis. Semin Neonatol 7:335-349, 2002.
43. Goldman S, Ellis R, Dhar V, Cairo MS: Rationale and potential use of cytokines in the prevention and treatment of neonatal sepsis. Clin Perinatol 25:699-710, 1998.
44. Perez EM, Weisman LE: Novel approaches to the prevention and therapy of neonatal bacterial sepsis. Clin Perinatol 24:213-229, 1997.
45. Bilgin K, Yaramis A, Haspolat K, Tas MA, Gunbey S, Derman O: A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 107:36-41, 2001.
46. Miura E, Procianoy RS, Bittar C, Miura CS, Miura MS, Mello C, Christenscn RD: A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics 107:30-35, 2001.
47. Carr R, Modi N, Dore C: G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev CD003066, 2003.
48. Rosenbloom AJ, Linden PK, Dorrance A, Penkosky N, Cohen-Melamed MH, Pinsky MR: Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest 127:2139-2150, 2005.
49. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W: Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3:678-681, 1997.
50. Cioffi WG Jr, Burleson DG, Jordan BS, Becker WK, McManus WF, Mason AD Jr, Pruitt BA Jr: Effects of granulocyte-macrophage colony-stimulating factor in burn patients. Arch Surg 126:74-79, 1991.